CARSGEN-B (02171) announced that on February 12, 2026 (after trading hours), its indirectly wholly-owned subsidiary, Shanghai Kaixing Diagnostic Technology, entered into a strategic cooperation agreement with Shanghai Jingong Enterprise Development, a key platform company in the Jinshan Bay Area High-Tech Park. The agreement involves a total investment of up to RMB 370 million to construct an advanced commercial production base for CAR-T cell therapies in Shanghai's Jinshan District.

This initiative is closely aligned with the company's commercialization timeline for multiple CAR-T cell therapy products. These include the already launched product and those under new drug application review, such as a CAR-T therapy for solid tumors. The new facility will also lay the groundwork for future large-scale production of several universal CAR-T cell therapy candidates.

Expanding CAR-T production capacity to meet international standards is a core strategy to support the commercial launch of multiple products and enhance global competitiveness. Under this agreement, the company is not required to make significant initial capital expenditures, thereby preserving valuable cash flow for core research and development and market expansion. A repurchase mechanism ensures the company can obtain full asset control after long-term operation, maintaining production stability while increasing flexibility in asset allocation.

Overall, this cooperation demonstrates the company's prudent financial planning and deep strategic positioning within the CAR-T cell therapy industry ecosystem. The project is highly consistent with national and local biomedical industry policies and has received significant attention and strong support from government authorities. This strategic partnership will help CARSGEN-B further consolidate its leading position in the global CAR-T cell therapy field and create long-term value for shareholders.